Advertisement
News
Subscribe to MDT Magazine News

Tesaro buys rights to Amgen lung cancer tech program

March 22, 2011 7:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Boston cancer-focused biotech startup Tesaro Inc. has landed an exclusive licensing deal with Amgen Inc., in which the Boston company will hold rights to Amgen's Anaplastic Lymphoma Kinase (ALK) technology.

Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board

March 22, 2011 6:38 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, March 22, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today announced the appointment of  J. Michael Pearson, currently Valeant's Chief Executive Officer (CEO), as Chairman of the Board of Directors, replacing Robert A. Ingram,...

TOPICS:

Dental Bib Chains are Potential Source for Infection and Disease

March 22, 2011 6:37 am | by Bio-Medicine.Org | Comments

CHARLOTTE, N.C., March 22, 2011 /- Wet, used towels left in the gym. Dirty tissues discarded by someone suffering from a nasty cold. A toothbrush discovered in a hotel room. Most of us would never use or even touch these items. But without knowing it, we may be sharing something that...

TOPICS:
Advertisement

Cinryze® (C1 Esterase Inhibitor Human) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 22, 2011 6:37 am | by Bio-Medicine.Org | Comments

EXTON, Pa., March 22, 2011 /- ViroPharma Incorporated (Nasdaq: VPHM ) today announced data presented in two poster presentations relating to Cinryze® (C1 esterase inhibitor [human]) at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18...

TOPICS:

FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree

March 22, 2011 6:36 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 22, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that Terumo Cardiovascular Systems Corporation (TCVS) of Ann Arbor, Mich., and two of its officers, Mark A. Sutter, president and chief executive officer, and Mark Lincoln,...

TOPICS:

Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR

March 22, 2011 6:34 am | by Bio-Medicine.Org | Comments

MADISON, N.J., March 22, 2011 /- Later this month, Quest Diagnostics (NYSE: DGX ) will demonstrate how physicians can benefit from $39 billion in federal incentives by utilizing Care360™ EHR . The 12-week, 10-city Care360 EHR Road Test tour was developed to help hospitals and...

TOPICS:

Instrumentation Laboratory Achieves Record Sales in 2010

March 22, 2011 6:34 am | by Bio-Medicine.Org | Comments

BEDFORD, Mass., March 22, 2011 /- Instrumentation Laboratory (IL) today announced total worldwide sales in 2010 of Euro 474.2 million ($644.9 million US). This represents 11.5% growth v. previous year in current, and 10.3% in local currencies.  In the Company's two major business...

TOPICS:

Labopharm cuts nearly 30 per cent of its workforce to reduce operating costs

March 22, 2011 5:45 am | by The Associated Press | Comments

Montreal-area drug developer Labopharm Inc. (TSX:DDS) is eliminating 38 positions, or nearly 30 per cent of its current workforce. The workforce reduction is expected to result in $3.8 million per year in savings.

Advertisement

Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule

March 22, 2011 5:33 am | by Bio-Medicine.Org | Comments

MADISON, Wis., March 22, 2011 /- Cellular Dynamics International (CDI) announced today that their two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to substantiate CDI's iCell® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of...

TOPICS:

GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients

March 22, 2011 5:32 am | by Bio-Medicine.Org | Comments

COCOA, Fla., March 22, 2011 /- GeNO LLC ( www.genollc.com ), a privately held, advanced development-stage technology company, today announced commencement of  the PHiano Study: A Phase 2, Dose-Escalation Trial for the Treatment of Pulmonary Hypertension in patients with Pulmonary...

TOPICS:

Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan

March 22, 2011 3:37 am | by Bio-Medicine.Org | Comments

MALVERN, Pa., March 22, 2011 /- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ) and Asahi Kasei Pharma Corporation announced today that they have entered into a long-term strategic alliance for the development, commercialization and supply of XIAFLEX® (collagenase clostridium...

TOPICS:

Reportlinker Adds Global Vitamins Industry

March 22, 2011 3:37 am | by Bio-Medicine.Org | Comments

NEW YORK, March 22, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Global Vitamins Industry http://www.reportlinker.com/p092490/Global-Vitamins-Industry.html This report analyzes the worldwide markets for Vitamins in US$ Million by the...

TOPICS:

Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio

March 22, 2011 3:37 am | by Bio-Medicine.Org | Comments

PITTSBURGH, March 22, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S....

TOPICS:

Finesse Launches MathLogic, SmartDose, and BlackBox Modules for Advanced Control With TruBio DV 4.0 Bioprocess Software

March 22, 2011 3:37 am | by Bio-Medicine.Org | Comments

SANTA CLARA, Calif., March 22, 2011 /- Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life science process applications, has announced the official launch of three new core modules for advanced control in its fourth generation TruBio DV software....

TOPICS:

Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements

March 22, 2011 3:34 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., March 22, 2011 /- Terumo Cardiovascular Systems (Terumo CVS), a U.S.-based subsidiary of Terumo Corporation of Tokyo, Japan, today announced it has agreed to the terms of a consent decree with the U.S. Food & Drug Administration (FDA) regarding quality system...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading